Third Rock Ventures III, L.P. - 08 Jun 2022 Form 4 Insider Report for Revolution Medicines, Inc. (RVMD)

Reporting relationship: 10%+ Owner
Issuer ticker: RVMD
Reported as of: 08 Jun 2022
Net transaction value: -$8,502,995
SEC form: 4
Accepted by SEC: 10 Jun 2022, 19:07:15 UTC
Prior SEC filing: 16 Nov 2021
Next SEC filing: 16 Aug 2022
Source filing: View source filing
Reporting owner signature: /s/ Kevin Gillis, Chief Operating Officer of TRV GP III, LLC, general partner of Third Rock Ventures GP III, L.P., general partner of Third Rock Ventures III, L.P.

Key filing fact

Third Rock Ventures III, L.P. filed Form 4 for Revolution Medicines, Inc. (RVMD) on 10 Jun 2022.

Key facts

This page summarizes Third Rock Ventures III, L.P.'s Form 4 filing for Revolution Medicines, Inc. (RVMD).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 10 Jun 2022, 19:07.

Change

Previous filing in this sequence was filed on 16 Nov 2021.
Current net transaction value: -$8,502,995.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RVMD transaction

Common Stock

Sale

Transaction value: $8,502,995
Shares: -419,901
Change %: -7.6%
Price: $20.25
Shares after: 5,104,130
Date: 08 Jun 2022
Ownership: Direct
Footnotes: F1, F2

RVMD holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 0
Date: 08 Jun 2022
Ownership: See footnote
Footnotes: F3

RVMD holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 129,258
Date: 08 Jun 2022
Ownership: Direct
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.25 to $20.41, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1).

Footnote F2

These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual manager of TRV GP III LLC is Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares

Footnote F3

Third Rock Ventures IV, L.P. ("TRV IV") directly holds 1,419,900 shares of Common Stock of the Issuer. The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of the reporting persons and TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.

Footnote F4

The shares are directly held by Tepper.